With new practice guidelines, it is important to understand how liver transplant (LT) 
treatment options for HCV-infected (HCV+) patients, and numerous studies have demonstrated the safety and efficacy of DAAs both pre-and post-LT. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] With the approval of DAAs, providers were faced with the challenge of deciding whether to initiate treatment of HCV+ transplant candidates pre-or post-LT. Weighing these options requires considering factors such as: a patient's disease severity and prognosis (as reflected in their model for end-stage liver disease
[MELD] score), hepatocellular carcinoma (HCC) status, the availability of a living donor, the availability of HCV+ donor livers, and the center's use of HCV+ donor livers. [19] [20] [21] [22] Prior to 2015, few guidelines or recommendations were available to inform these choices.
In 2015, the Infectious Disease Society of America (IDSA) and
American Association for the Study of Liver Diseases (AASLD) jointly published HCV treatment recommendations, detailing post-LT treatment guidelines. 23 These recommendations did not, however, directly address how, when, or which candidates LT centers should treat prior to LT, leading to varied opinions in the field. 8, 19, 20, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] In 2017, the International Liver Transplantation Society (ILTS) expert consensus statements provided recommendations for the management of both HCV+ liver transplant candidates and recipients.
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Despite this rapidly changing landscape, few studies have directly examined the impact of DAAs on center-level attitudes and treatment decisions for LT patients.
We hypothesized that the availability of DAAs would increase transplant centers' willingness to use HCV+ donor livers and to treat HCV overall, but centers might remain hesitant to treat certain groups of LT candidates without clear guidelines. The objective of this study was to survey US LT centers to describe changes in attitudes and practices related to HCV and LT before and after DAAs became available. To understand the impact of DAAs on LT, we surveyed the highest volume US LT centers from 11/2014 to 12/2015 to study whether treatment of HCV+ LT candidates and recipients and willingness to use HCV+ donors differed before and after DAA availability.
| ME THODS

| Source population
Transplant centers were identified using data from the Scientific 
| Survey administration
After center identification, survey participants were chosen using a two-stage process. First, initial contact information was derived through personal connections, PubMed, Internet searches, and phone calls or emails to transplant directors at each center. Then, each contact was asked to suggest the most appropriate representative at their center and assist with connecting this individual to the study team. Links to the survey were sent between November 2014 and December 2015 to the identified study participants to complete as a representative on behalf of their transplant center. All surveys were conducted using Qualtrics Survey Software. Non-respondents were sent a minimum of 3 and a maximum of 6 follow-up reminder emails.
| Survey design
This study was reviewed and acknowledged to be exempt by the candidates would be treated on the LT waitlist at their center, on a 5-point Likert scale from "never" to "always." Respondents were also asked to identify barriers to treating HCV+ LT candidates and recipients at their center by selecting any/all that applied from a list provided or selecting "other" and providing a free response.
| Statistical analysis
We used separate linear regression models to measure the associa- were most often hepatologists affiliated with academic centers (n = 50) and hepatologists in the community (n = 8) ( Table 1) .
Of the four centers selecting "other," respondents identified 
| HCV treatment of candidates based on clinical disease
Within each center, the degree to which treatment of HCV+ candidates changed after DAAs differed for candidates with low MELD (≤15), intermediate/high MELD (>15), and HCC ( Figure 1 ). We did not find survey responses regarding treatment of the various HCV+ candidate groups to be associated with center HCV prevalence in any of the linear or logistic regression models (all were P > 0.05) (see Supplemental Materials).
| Candidates with low MELD
Before DAAs, 13 centers (24.1%) indicated that candidates with low MELD would be treated "most of the time" or "always" while on the waitlist ( Figure 2A ). After DAAs, 49 centers (90.8%) said low MELD candidates would be treated "most of the time" or "always." For eight centers (14.8%), there was no change in how often low MELD candidates were treated before and after DAAs, while 46 (85.2%) increased treatment after DAAs (Table 3) .
| Candidates with intermediate/high MELD
Before DAAs, one center (1.9%) indicated that candidates with intermediate/high MELD would be treated "most of the time" or "always" while TA B L E 1 Respondent medical specialties and transplant program role; affiliations and specialties of physicians primarily responsible for treating hepatitis C virus-infected (HCV+) candidates and recipients
Respondent characteristics n (%)
Medical specialty 
| Candidates with HCC
Before DAAs, 8 centers (14.9%) indicated that candidates with HCC would be treated "most of the time" or "always" while on the waitlist ( Figure 2C ). After DAAs, 38 centers (70.3%) said that candidates with HCC would be treated "most of the time" or "always."
For nine centers (16.7%), there was no change how often candidates with HCC were treated before and after DAAs, while 43 (79.6%) increased treatment after DAAs.
| Candidates with living donors
Before DAAs, four centers (7.5%) indicated that candidates with living donors would be treated "most of the time" or "always" while on the waitlist ( Figure 2D ). After DAAs, 23 centers (42.6%) said that candidates with living donors would be treated "most of the time"
or "always." For two centers (3.7%), there was no change how often candidates with living donors were treated before and after DAAs, while 26 (48.1%) increased treatment after DAAs.
| HCV treatment of recipients
The proportion of HCV+ recipients among surveyed centers decreased from an average of 40.8% pre-survey to 26.8% post-survey (Table 2) .
Before DAAs, 20 centers (37.0%) indicated that HCV+ recipients would be treated "most of the time" or "always" post-LT. After DAAs, 52 centers (96.3%) (including the eight centers, where local providers were primarily (Table 4) . We did not find survey responses regarding treatment of HCV+ recipients to be associated with center HCV prevalence in either the linear or logistic regression models (both were P > 0.05).
| Willingness to transplant and retransplant HCV+ recipients
After DAAs, 14 centers (25.9%) reported increased willingness to perform LTs for HCV+ recipients, with 40 centers (74.1%) experiencing no change in willingness to transplant these patients. Before DAAs, six centers (11.3%) indicated that recipients with recurrent HCV and liver failure would be retransplanted "most of the time" or "always."
After DAAs, 36 centers (66.7%) said they would retransplant these patients "most of the time" or "always." For 11 centers (20.8%), there was no change how often recipients with recurrent HCV and liver failure would be retransplanted before and after DAAs, while 41 (77.4%) increased willingness to retransplant these patients after DAAs (Table 4) .
We did not find willingness to re-transplant HCV+ recipients to be associated with center HCV prevalence in either the linear or logistic regression models (both were P > 0.05).
| Selection criteria and use of HCV+ donor organs
On average, the use of HCV+ donors among surveyed centers doubled from the pre-survey to post-survey period (3.9% to 8.0%; (Table 2 ).
TA B L E 3 How often centers would treat various hepatitis C virus-infected (HCV+) candidates (those with low model for end-stage liver
| Barriers to treatment
Third party payers were the most commonly selected obstacle (n = 43) followed by concerns for co-morbidities in this patient population (n = 16). Free responses included: cost of the drug, case load of limited staff, clinical instability of LT candidates on the waitlist, patient refusal of treatment, and concern for lowering patients' MELD scores and thereby decreasing their chances of receiving an organ offer (Table 5 ).
| D ISCUSS I ON
This national survey collected data from 57 of the highest volume US LT centers (71.3% response rate), predominantly provided by hepatologists (82.5%) identified as representatives for their center.
Only half of these centers (50.9%) reported having standardized institutional protocols for treating HCV+ patients on the waitlist or post-LT. Hepatologists affiliated with academic centers (n = 50) or hepatologists in the community (n = 8) were primarily responsible for treating HCV+ transplant patients. Nearly all centers (98.1%) used HCV+ deceased donor organs for HCV+ recipients, with 63.0% using pre-specified, mostly age-based, criteria for selecting HCV+ donors.
Of these, 85.3% have modified HCV+ donor selection criteria since the approval of DAAs, primarily by relaxing age-based restrictions. vey. 35 Unpredictable organ offers complicate timing the initiation of DAA therapy for LT candidates, particularly those with higher MELD scores who are less clinically stable and more likely to be transplanted. 21, 38 In the DAA era we found that centers were much more likely to universally treat candidates with MELD ≤15 (31.5%)
than those with MELD >15 (1.9%), in keeping with subsequently institutional protocols to expand the use of HCV+ donor livers for HCV− LT candidates may also deserve further review.
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This study has several limitations that merit consideration. First, we relied on our contacts at each LT center to identify an individual to represent the views of their center as a whole. Since there may be different attitudes and practices within a single LT center, it may not be possible to capture these in each response. We cannot rule out the potential that survey responses more closely reflected a respondent's perception than their center's practices, particularly for centers with no specific protocols to report. We were also only able to sample a portion of all US transplant centers. However, we believe that the high response rate, together with our focus on high volume centers, likely yields results with little responder bias that represent the most relevant data. Finally, this survey did not collect more specific, granular information on how many HCV+ patients were treated at each center on the waitlist or post-LT, which particular DAAs were used, or how care of HCV+ transplant patients might transition from transplant centers to local providers. Instead, we sought to describe the national landscape of centers' attitudes and general treatment practices of HCV+ LT patients in the US before and after DAA availability.
In conclusion, we surveyed 57 of the highest volume US LT centers (71.3% response rate) to learn how DAAs have impacted practices and attitudes toward treating HCV+ LT candidates and recipients and using HCV+ donors. Overall, DAAs increased LT centers' willingness to use HCV+ donors more broadly and to treat, transplant, and retransplant HCV+ candidates and recipients, but the management of particular candidate groups still varies across centers. 
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